ATE173630T1 - Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren - Google Patents

Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren

Info

Publication number
ATE173630T1
ATE173630T1 AT94905355T AT94905355T ATE173630T1 AT E173630 T1 ATE173630 T1 AT E173630T1 AT 94905355 T AT94905355 T AT 94905355T AT 94905355 T AT94905355 T AT 94905355T AT E173630 T1 ATE173630 T1 AT E173630T1
Authority
AT
Austria
Prior art keywords
interferon
treatment
inflammatory bowel
bowel disease
gamma inhibitors
Prior art date
Application number
AT94905355T
Other languages
English (en)
Inventor
Avi J Ashkenazi
Rebecca H R Ward
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE173630T1 publication Critical patent/ATE173630T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT94905355T 1992-12-29 1993-12-09 Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren ATE173630T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99783592A 1992-12-29 1992-12-29

Publications (1)

Publication Number Publication Date
ATE173630T1 true ATE173630T1 (de) 1998-12-15

Family

ID=25544454

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94905355T ATE173630T1 (de) 1992-12-29 1993-12-09 Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren

Country Status (12)

Country Link
US (5) US6558661B1 (de)
EP (1) EP0695189B1 (de)
JP (1) JP3887011B2 (de)
AT (1) ATE173630T1 (de)
AU (1) AU678429B2 (de)
CA (1) CA2148907C (de)
DE (1) DE69322289T2 (de)
DK (1) DK0695189T3 (de)
ES (1) ES2126094T3 (de)
IL (2) IL108007A (de)
WO (1) WO1994014467A1 (de)
ZA (1) ZA939577B (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20040049014A1 (en) * 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
EP0563487A1 (de) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoklonale Antikörper gegen den Interferonrezeptor, mit neutralisierender Aktivität gegen Typ I-Interferon
DK0695189T3 (da) * 1992-12-29 1999-08-09 Genentech Inc Behandling af inflammatorisk tarmsygdom med IFN-gammainhibitorer
US20020025316A1 (en) 1995-08-18 2002-02-28 Ferguson Mark Williams James Pharmaceutical composition containing inhibitors of interferon-gamma
GB2304342A (en) * 1995-08-18 1997-03-19 Univ Manchester Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma
AU2452797A (en) * 1996-04-10 1997-10-29 Board Of Trustees Of The University Of Illinois, The Interferon-gamma anti-inflammatory methods, compounds, and pharmaceutical compositions
DE69927520T2 (de) 1998-12-09 2006-06-22 Protein Design Labs, Inc., Fremont Verwendung von il-12 antikörpern zur behandlung von psoriasis
US6346247B1 (en) * 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
US6348316B1 (en) 2000-04-12 2002-02-19 Cedars-Sinai Medical Center Genetic testing for determining the risk of pouchitis development
GB0009503D0 (en) * 2000-04-17 2000-06-07 Univ Liverpool Screening method for compounds
CA2407426A1 (en) 2000-04-28 2001-11-08 Planet Biotechnology, Inc. Immunoadhesin for the prevention of rhinovirus infection
AU2003214023A1 (en) * 2002-03-12 2003-09-22 Novo Nordisk A/S Dimeric tf antagonist comprising two factor vii polypeptides
WO2003097658A2 (en) 2002-05-16 2003-11-27 Glycomimetics, Inc. Compounds and methods for inhibiting selectin-mediated function
WO2003097082A2 (en) * 2002-05-17 2003-11-27 Protein Design Labs Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
JP2006502986A (ja) * 2002-07-03 2006-01-26 グリコミメティクス， インコーポレイテッド 新脈管形成に関与する医学的状態の診断および治療のための組成物および方法
WO2004017921A2 (en) * 2002-08-23 2004-03-04 Zymogenetics, Inc. Method for treating inflammatory bowel disease
WO2004034988A2 (en) 2002-10-16 2004-04-29 Amgen Inc. Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
EP1900753B1 (de) 2002-11-08 2017-08-09 Ablynx N.V. Verfahren zur Verabreichung therapeutischer Polypeptide und Polypeptide dafür
CA2489208C (en) * 2003-02-24 2012-11-06 Morinaga Milk Industry Co., Ltd. Interleukin-6 suppressive agent
AU2004232362C1 (en) 2003-04-23 2008-05-29 E. R. Squibb & Sons, L.L.C. Compositions and methods for the therapy of inflammatory bowel disease
US20040219158A1 (en) * 2003-05-02 2004-11-04 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria
GB0323793D0 (en) * 2003-10-10 2003-11-12 Imp College Innovations Ltd Methods
WO2005054264A2 (en) * 2003-11-19 2005-06-16 Glycomimetics, Inc. Glycomimetic antagonists for both e- and p-selectins
EP1763533B1 (de) * 2003-11-19 2008-01-09 GlycoMimetics, Inc. Spezifischer antagonist sowohl für e- als auch p-selektine
US20050260155A1 (en) * 2004-05-18 2005-11-24 Gopala Kovvali Compositions and methods for treatment of ulcerative colitis
US7662381B2 (en) 2004-06-21 2010-02-16 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses
US20060040258A1 (en) * 2004-08-23 2006-02-23 Huiyan Guo Water-soluble conjugates and methods of preparation
US8201377B2 (en) * 2004-11-05 2012-06-19 Faus Group, Inc. Flooring system having multiple alignment points
PT1848744E (pt) 2005-01-27 2012-04-24 Novimmune Sa Anticorpos anti-interferão gama e os seus processos de utilização
US20060205090A1 (en) * 2005-03-14 2006-09-14 Newton Michael W Water-soluble conjugates for electrochemical detection
US20090036386A1 (en) * 2005-05-25 2009-02-05 Glycomimetics, Inc Heterobifunctional compounds for selectin inhibition
US7608430B2 (en) * 2005-07-08 2009-10-27 Regeneron Pharmaceuticals, Inc. Interferon-γ antagonists and therapeutic uses thereof
CN101291946B (zh) * 2005-08-09 2011-06-29 糖模拟物有限公司 对来自假单胞菌的pa-il凝集素、pa-iil凝集素或其两者的糖模拟物抑制剂
PL2264043T3 (pl) 2005-09-02 2018-04-30 Glycomimetics, Inc. Heterobifunkcyjne inhibitory pan-selektyny
US20090176717A1 (en) * 2006-06-01 2009-07-09 Glycomimetics, Inc. Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
EP2074132B1 (de) 2006-10-12 2013-05-15 GlycoMimetics, Inc. Glycomimetischer ersatz für hexosen und n-acetyl-hexosamine
AU2008216794A1 (en) * 2007-02-09 2008-08-21 Glycomimetics, Inc. Methods of use of glycomimetics with replacements for hexoses and N-acetyl hexosamines
US8039442B2 (en) 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith
WO2009126556A1 (en) 2008-04-08 2009-10-15 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
CN102088983B (zh) * 2008-06-13 2013-01-30 糖模拟物有限公司 利用选择的糖模拟化合物的血液癌症的治疗
NZ590667A (en) * 2008-07-02 2013-01-25 Emergent Product Dev Seattle Tgf-b antagonist multi-target binding proteins
JP2011526792A (ja) * 2008-07-02 2011-10-20 エマージェント プロダクト デベロップメント シアトル， エルエルシー ＴＮＦ−αアンタゴニスト多重標的結合性タンパク質
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
CA2760292A1 (en) 2009-05-01 2010-11-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
US9848760B2 (en) * 2009-06-29 2017-12-26 Gearbox, Llc Devices for continual monitoring and introduction of gastrointestinal microbes
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
SG11201402490XA (en) 2011-11-23 2014-06-27 Amgen Inc Methods of treatment using an antibody against interferon gamma
KR102055958B1 (ko) 2011-12-22 2019-12-13 글리코미메틱스, 인크. E-셀렉틴 길항제 화합물, 조성물, 및 이용 방법
US9309318B2 (en) 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
US9867841B2 (en) 2012-12-07 2018-01-16 Glycomimetics, Inc. Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells
EP2970483A2 (de) 2013-03-15 2016-01-20 Amgen Inc. Verfahren und zusammensetzungen im zusammenhang mit anti-ccr7-antigen-bindenden proteinen
KR20230109779A (ko) 2013-03-27 2023-07-20 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전
EP3022295A4 (de) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signatur des tl1a (tnfsf15)-signalweges
JP6689854B2 (ja) 2014-12-03 2020-04-28 グリコミメティクス， インコーポレイテッド Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤
US20180051078A1 (en) * 2015-03-16 2018-02-22 Cedars-Sinai Medical Center Methods of treating inflammatory bowel disease with ifn-gamma therapy
CN121588213A (zh) 2015-05-07 2026-03-03 瑞典孤儿比奥维特鲁姆股份公司 用于诊断和治疗cxcl9和其它生物标志物水平升高的患者的病症
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
JP2019502727A (ja) 2016-01-22 2019-01-31 グリコミメティクス， インコーポレイテッド Ｐａ−ｉｌおよび／またはｐａ−ｉｉｌレクチンの糖模倣体阻害剤
WO2017151708A1 (en) 2016-03-02 2017-09-08 Glycomimetics, Inc. Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
KR20240095481A (ko) 2016-03-17 2024-06-25 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
US11433086B2 (en) 2016-08-08 2022-09-06 Glycomimetics, Inc. Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4
AU2017341065B2 (en) 2016-10-07 2023-04-06 Crescent Biopharma, Inc. Highly potent multimeric E-selectin antagonists
US10266745B2 (en) * 2017-02-03 2019-04-23 Saudi Arabian Oil Company Anti-bit balling drilling fluids, and methods of making and use thereof
EP3596096A1 (de) 2017-03-15 2020-01-22 GlycoMimetics, Inc. Galactopyranosyl-cyclohexyl-derivate als e-selectin-antagonisten
JP7275131B2 (ja) 2017-11-30 2023-05-17 グリコミメティクス， インコーポレイテッド 骨髄浸潤リンパ球を動員する方法、およびその使用
KR20200104889A (ko) 2017-12-29 2020-09-04 글리코미메틱스, 인크. E-셀렉틴 및 갈렉틴-3의 이종이기능성 억제제
KR20200128025A (ko) 2018-03-05 2020-11-11 글리코미메틱스, 인크. 급성 골수성 백혈병 및 관련 병태의 치료 방법
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
AU2024334289A1 (en) 2023-08-25 2026-04-09 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
GB8519848D0 (en) 1985-08-07 1985-09-11 Schweiz Rotes Kreuz Treatment of chronic inflammatory disease
IL78444A (en) 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
EP0269408A3 (de) 1986-11-26 1989-08-30 Genentech, Inc. TGF-Beta für die Behandlung von entzündlichen Erkrankungen
IL88378A (en) 1988-11-14 2000-11-21 Yeda Res & Dev Human interferon-gamma binding proteins their manufacture and pharmaceutical compositions comprising them
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU625866B2 (en) 1989-04-19 1992-07-16 F. Hoffmann-La Roche Ag Soluble interferon-gamma receptors and methods for their production
US5061786A (en) 1989-05-25 1991-10-29 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
IL91562A0 (en) 1989-09-07 1990-04-29 Yeda Res & Dev Interferon-gamma receptor fragment and its production
DE69104356T2 (de) 1990-04-24 1995-03-02 Schering Corp Lösliche verkürzte interferon-gamma rezeptoren.
EP0550650B1 (de) 1990-09-27 1995-12-27 Schering Corporation Humane gammainterferonantagonisten
DK0695189T3 (da) * 1992-12-29 1999-08-09 Genentech Inc Behandling af inflammatorisk tarmsygdom med IFN-gammainhibitorer
CA2114168A1 (en) 1993-03-05 1994-09-06 Zlatko Dembic Chimeric human interferon-gamma-receptor/immunoglobulin polypeptides
JPH0746628A (ja) * 1993-06-29 1995-02-14 Toshiba Corp 画像信号符号化装置及び画像信号復号化装置
HK1044159A1 (zh) 1998-12-01 2002-10-11 蛋白质设计实验室股份有限公司 抗γ-干扰素的人化抗体
WO2003097082A2 (en) 2002-05-17 2003-11-27 Protein Design Labs Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
US20050019323A1 (en) 2002-05-22 2005-01-27 Protein Design Labs, Inc. Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies

Also Published As

Publication number Publication date
WO1994014467A1 (en) 1994-07-07
DE69322289D1 (de) 1999-01-07
US20070104712A1 (en) 2007-05-10
US7449176B2 (en) 2008-11-11
IL124478A0 (en) 1998-12-06
DK0695189T3 (da) 1999-08-09
DE69322289T2 (de) 1999-05-20
EP0695189A1 (de) 1996-02-07
AU678429B2 (en) 1997-05-29
US6558661B1 (en) 2003-05-06
IL108007A0 (en) 1994-04-12
US7300656B2 (en) 2007-11-27
ZA939577B (en) 1995-06-21
ES2126094T3 (es) 1999-03-16
JP3887011B2 (ja) 2007-02-28
CA2148907C (en) 2008-07-08
AU5898894A (en) 1994-07-19
US20070020268A1 (en) 2007-01-25
IL108007A (en) 2005-08-31
US20030012790A1 (en) 2003-01-16
CA2148907A1 (en) 1994-07-07
JPH08504817A (ja) 1996-05-28
US20030012787A1 (en) 2003-01-16
EP0695189B1 (de) 1998-11-25

Similar Documents

Publication Publication Date Title
ATE173630T1 (de) Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren
EA200100572A1 (ru) Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
MX9602818A (es) Un metodo de tratamiento de infeccion parasitaria usando antagonistas ige.
BG101841A (bg) Инхибитори на клетъчна адхезия
DE69622894D1 (de) Substituierte Sulfonylphenylheterocyclen als Cyclooxygenase-2 und 5- Lipoxygenase Inhibitoren
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
DK0705100T3 (da) Terapeutiske substituerede guanidiner
TR199801151T2 (xx) Trombin inhibit�r� �n ila�lar.
TR199902545T2 (xx) Kalp damar hastal�klar�n�n �nlenmesinde siklooksijenaz-2 inhibit�rlerini kullanma y�ntemi
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
LV12209A (lv) Ar fenilgrupu aizvietoti heterocikli ka ciklooksigenazes-2 inhibitori
NO996578L (no) Urokinase-inhibitorer
EP0876387A4 (de) Verfahren zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren
KR950700323A (ko) 엔케팔리나제 및 안지오텐신 전환 효소의 억제제로서 유용한 아미노아세틸머캅토아세틸아미드 유도체(Aminoacetylmercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ACE)
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
DK0603301T3 (da) Farmaceutisk præparat indeholdende et urikosurikon og en excitatorisk-aminosyre-antagonist
DE69413789D1 (de) 2-amino-4-phenyl-4-oxo-buttersäure-derivate mit kynureninase und/oder kynurenin-3-hydroxylase inhibierender wirkung
DE69720996D1 (de) Neue pharmazeutische zusammensetzungen von steroid-nitratester zur verwendung als enzündungshemmer
MXPA04002565A (es) Combinacion de un inhibidor de il-1/18 con un inhibidor de tnf para el tratamiento de inflamacion.
TR199901703T2 (xx) Siklooksijenaz-2 inhibit�rlerini anti-anjiyojenik ajanlar olarak kullanma y�ntemi.
DE69423533D1 (de) Zubereitungen zur Behandlung von Impotenz, die ein Alpha-1 inhibitor und ein Alpha-2 inhibitor enthalten
MXPA94009086A (es) Guanidinas sustituidas terapeuticas.
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
NO993627L (no) Anvendelse av en forbindelse for fremstilling av et legemiddel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification